This inventor holds 1 USPTO granted patent. Top assignees: Chinook Therapeutics, Inc., Novartis Ag. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 10 
1 out of 3,975 
Years Active: 2021
Title: Jacob Robert Bruml: Innovator in Immune Stimulation
Introduction
Jacob Robert Bruml is an accomplished inventor based in San Francisco, CA. He is known for his significant contributions to the field of immune stimulation through his innovative research and development of nucleic acid compounds.
Latest Patents
Jacob holds a patent for "Locked nucleic acid cyclic dinucleotide compounds and uses thereof." This invention provides highly active locked nucleic acid cyclic-dinucleotide (LNA-CDN) immune stimulators that activate dendritic cells via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes). The LNA-CDNs are formulated in a composition that induces human STING-dependent type I interferon production, featuring cyclic dinucleotides with at least one 2', 4' locked nucleic acid.
Career Highlights
Throughout his career, Jacob has worked with notable companies such as Chinook Therapeutics, Inc. and Novartis AG. His work has focused on advancing therapeutic solutions that leverage the immune system's capabilities.
Collaborations
Jacob has collaborated with esteemed colleagues, including David Braun Kanne and Chudi Obioma Ndubaku, contributing to the advancement of research in his field.
Conclusion
Jacob Robert Bruml is a pioneering inventor whose work in immune stimulation through innovative nucleic acid compounds has the potential to significantly impact therapeutic strategies. His contributions continue to shape the landscape of immunology and biotechnology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile